Inari Medical, Inc. (NASDAQ:NARI) Shares Bought by Prudential Financial Inc.

Prudential Financial Inc. grew its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 9.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 170,400 shares of the company’s stock after purchasing an additional 14,290 shares during the period. Prudential Financial Inc. owned approximately 0.29% of Inari Medical worth $8,699,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of NARI. Smartleaf Asset Management LLC increased its stake in Inari Medical by 128.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock valued at $33,000 after buying an additional 356 shares during the period. R Squared Ltd bought a new position in shares of Inari Medical in the fourth quarter valued at approximately $45,000. GAMMA Investing LLC increased its stake in shares of Inari Medical by 66.8% during the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock valued at $100,000 after acquiring an additional 786 shares during the period. KBC Group NV raised its holdings in Inari Medical by 31.5% during the fourth quarter. KBC Group NV now owns 2,333 shares of the company’s stock worth $119,000 after purchasing an additional 559 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. raised its holdings in Inari Medical by 44.2% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock worth $128,000 after purchasing an additional 954 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Stock Performance

Shares of NARI stock opened at $79.97 on Friday. The firm has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $79.99. The firm’s fifty day simple moving average is $79.87 and its 200 day simple moving average is $61.44.

Analyst Ratings Changes

Several brokerages have recently issued reports on NARI. Robert W. Baird reiterated a “neutral” rating and set a $80.00 price target (down from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $80.00 target price (up from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. Oppenheimer assumed coverage on shares of Inari Medical in a report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price target for the company. Canaccord Genuity Group restated a “hold” rating and set a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, William Blair reiterated a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $68.00.

Insiders Place Their Bets

In related news, Director William Hoffman sold 200,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $60.47, for a total value of $12,094,000.00. Following the completion of the sale, the director now owns 238,987 shares in the company, valued at approximately $14,451,543.89. This trade represents a 45.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.